Ophthalmology Times Staff Reports

Studies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.

The SARM1 gene is a key driver in the damage that ultimately leads to impaired vision.

The cell therapy yielded improvements in visual acuity and central corneal thickness.

Avalanche Biotechnologies Inc. and Lonza have announced a manufacturing collaboration focused on process development and scale-up efforts for the manufacturing of adeno-associated viral (AAV) vectors for gene therapy.